Advertisement
U.S. markets closed

RayzeBio, Inc. (RYZB)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
62.49+0.01 (+0.02%)
At close: 04:00PM EST
62.51 +0.02 (+0.03%)
After hours: 08:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close62.48
Open62.49
Bid62.49 x 41800
Ask62.50 x 2200
Day's Range62.48 - 62.50
52 Week Range17.95 - 62.51
Volume282,719
Avg. Volume745,490
Market Cap3.75B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.08
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est53.33
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for RYZB

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • RayzeBio, Inc.
    LNTH: Raising target price to $60.00LANTHEUS HOLDINGS INC has an Investment Rating of HOLD; a target price of $60.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
    Rating
    Fair Value
    Economic Moat
    4 days agoArgus Research
View more
  • Business Wire

    Bristol Myers Squibb Announces Expiration of RayzeBio Tender Offer

    PRINCETON, N.J., February 23, 2024--Bristol Myers Squibb (NYSE: BMY) today announced that its previously announced tender offer (the "Offer") to acquire all of the outstanding shares of RayzeBio, Inc. (Nasdaq: RYZB) common stock for a purchase price of $62.50 per share in cash, or approximately $4.1 billion, expired at one minute after 11:59 p.m., Eastern Time, on February 22, 2024 (the "Expiration Time").

  • Bloomberg

    Bristol Myers is Tapping US High-Grade Bond Market to Fund M&A

    (Bloomberg) -- Bristol Myers Squibb sold $13 billion of bonds to help finance its acquisitions of Karuna Therapeutics Inc. and RayzeBio Inc., a deal that gathered orders exceeding $85 billion, according to a person with knowledge of the matter.Most Read from BloombergJapan Loses Its Spot as World's Third-Largest Economy as It Slips Into RecessionIsrael Quits Ceasefire Talks Over ‘Delusional’ Hamas DemandsThe Brutal Reality of Plunging Office Values Is HereTrump Eyes NATO Makeover, Hurried Peace

  • Business Wire

    Bristol Myers Squibb and RayzeBio Announce Expiration of HSR Act Waiting Period

    PRINCETON, N.J. & SAN DIEGO, February 12, 2024--Bristol Myers Squibb (NYSE: BMY) and RayzeBio, Inc. (Nasdaq: RYZB) today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, or HSR Act, in connection with Bristol Myers Squibb’s previously announced tender offer to acquire all of the outstanding shares of RayzeBio common stock for a purchase price of $62.50 per share in cash, or approximately $4.1 billion. The expiration of the waiting per